Last reviewed · How we verify
Goserelin, Histrelin, Leuprolide & Triptorelin
Goserelin, Histrelin, Leuprolide, and Triptorelin are gonadotropin-releasing hormone (GnRH) agonists that work by mimicking the action of natural GnRH to suppress the production of sex hormones.
Goserelin, Histrelin, Leuprolide, and Triptorelin are gonadotropin-releasing hormone (GnRH) agonists that work by mimicking the action of natural GnRH to suppress the production of sex hormones. Used for Prostate cancer, Endometriosis.
At a glance
| Generic name | Goserelin, Histrelin, Leuprolide & Triptorelin |
|---|---|
| Sponsor | VA Office of Research and Development |
| Drug class | GnRH agonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By continuously stimulating the GnRH receptors, these drugs downregulate the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a decrease in sex hormone production. This mechanism is primarily used to treat hormone-sensitive cancers and conditions such as prostate cancer and endometriosis.
Approved indications
- Prostate cancer
- Endometriosis
Common side effects
- Hot flashes
- Nausea
- Headache
- Fatigue
- Diarrhea
Key clinical trials
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (PHASE3)
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (PHASE3)
- Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial (PHASE2)
- Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (PHASE2, PHASE3)
- Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer (PHASE3)
- Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer (PHASE2)
- A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: